Stemcells (STEM) Posts Mixed Q1 Results

Go back to Stemcells (STEM) Posts Mixed Q1 Results

StemCells (STEM) Posts Q1 Results and Data Is Coming, Maxim Group Says

May 15, 2014 7:39 AM EDT

Maxim Group analyst Jason Kolbert reiterated a Buy rating and $2.50 price target on StemCells (NASDAQ: STEM) following first quarter results and an overall update on the current clinical programs with a focus on PI/II spine and AMD trials.

The analyst... More